- ￥2400
- PLLABS
- 加拿大
- PL0302159
- 2025年07月10日
- WB: 1:100-500 E: 1:500-1000 IP: 1:20-100 IHC: 1:100-500 IF: 1:100-500
- Rabbit
- Hu, Mo, Rat, Chi, Cow, Hor, Sheep, Guinea Pig
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 免疫原：
PhosphoPeptide derived from human Smad3 around the phosphorylation site of Ser213 [PM(p-S)PA].
- 亚型：
Rabbit Polyclonal IgG
- 形态：
液态
- 保存条件：
保存于-20℃
- 克隆性：
多克隆
- 标记物：
无标记（PLlabs可供应生物素、酶、荧光素标记的抗体）
- 适应物种：
Hu, Mo, Rat, Chi, Cow, Hor, Sheep, Guinea Pig
- 保质期：
按说明书条件可保存1-2年
- 抗原来源：
见详细说明资料
- 目录编号：
PL0302159
- 级别：
超纯
- 库存：
大量
- 供应商：
华拓生物
- 宿主：
Rabbit
- 应用范围：
WB: 1:100-500 E: 1:500-1000 IP: 1:20-100 IHC: 1:100-500 IF: 1:100-500
- 浓度：
1mg/ml
- 靶点：
phospho-Smad3(Ser213)
- 抗体英文名：
phospho-Smad3(Ser213) Antibody
- 抗体名：
磷酸化细胞信号转导分子SMAD3抗体
- 规格：
0.1ml
Storage Buffer: PBS, pH 7.4(1%BSA and 0.1% Sodium azide)
Background：
This product for research use only, not for use in humans, therapeutic or diagnostic procedures.
PLLABS坚持提供高质量的产品和专业的技术服务，并提供完善的技术支持和售后服务。
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Using Phospho‐Motif Antibodies to Determine Kinase Substrates
comprising both the phosphorylated residue and the surrounding residues that determine kinase specificity, with degenerate residues taking up the remaining positions. Currently, several categories of phospho?motif antibody are commercially available
Optimized Protocol to Make Phospho-Specific Antibodies that Work
, not simply its level of expression. In this review, we will discuss both the design of the phosphopeptide immunogen and immunization. The affinity purification of the phospho-specific antibody as well as the methods most suitable for characterizing
Absorption Control in Immunohistochemistry Using Phospho-Peptides Immobilized on Magnetic Beads
neutralization of phospho-specific antibodies with phospho-peptides immobilized on magnetic beads. This technique allows for sequestration of antibody–peptide complex from the incubation solution, minimizing the risk of formation of unblocked antibodies capable
技术资料暂无技术资料 索取技术资料
